We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.13%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$18.4M
Cap. Flow
-$139M
Cap. Flow %
-6.88%
Top 10 Hldgs %
53.81%
Holding
65
New
13
Increased
7
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
NKTX icon
Nkarta
NKTX
+$43.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$19.6M
4
KURA icon
Kura Oncology
KURA
+$19.4M
5
ALLO icon
Allogene Therapeutics
ALLO
+$16.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$188M
2
IMGN
Immunogen Inc
IMGN
+$87.8M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$79.1M
4
ARGX icon
argenx
ARGX
+$23.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$168M 8.32%
3,421,541
– –
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$147M 7.27%
2,100,000
– –
RVMD icon
3
Revolution Medicines
RVMD
$39.6B
$138M 6.81%
4,279,464
– –
TYRA icon
4
Tyra Biosciences
TYRA
$1.91B
$106M 5.22%
6,448,359
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$101M 5.01%
1,726,000
– –
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.47B
$96.7M 4.77%
2,202,812
– –
MRUS
7
DELISTED
Merus
MRUS
$85.6M 4.23%
1,900,000
– –
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.82B
$84.1M 4.16%
650,000
– –
NUVL
9
DELISTED
Nuvalent
NUVL
$84.1M 4.15%
1,120,192
– –
ONC
10
BeOne Medicines Ltd
ONC
$32.4B
$78.2M 3.86%
500,000
– –
TNGX icon
11
Tango Therapeutics
TNGX
$4.65B
$65.1M 3.22%
8,198,642
– –
NKTX icon
12
Nkarta
NKTX
$186M
$60.6M 2.99%
5,607,350
+4,167,350
+289% +$43.3M
FATE icon
13
Fate Therapeutics
FATE
$324M
$60.3M 2.98%
8,215,910
+7,715,910
+1,543% +$47.8M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$44.1M 2.18%
1,727,388
+606,061
+54% +$9.5M
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$42.4M 2.09%
1,676,733
– –
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$376M
$39.5M 1.95%
1,466,051
– –
ARGX icon
17
argenx
ARGX
$53.8B
$39.4M 1.94%
100,000
-60,000
-38% -$23.2M
LEGN icon
18
Legend Biotech
LEGN
$4.31B
$33.7M 1.66%
600,000
– –
AXSM icon
19
Axsome Therapeutics
AXSM
$11.8B
$31.9M 1.58%
400,000
– –
RCUS icon
20
Arcus Biosciences
RCUS
$3.44B
$30.2M 1.49%
1,602,200
– –
ANAB icon
21
AnaptysBio
ANAB
$1.72B
$29.3M 1.45%
1,300,000
– –
IMVT icon
22
Immunovant
IMVT
$8.27B
$26.7M 1.32%
825,000
-175,000
-18% -$6.38M
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.6B
$25.8M 1.28%
600,000
– –
ARVN icon
24
Arvinas
ARVN
$517M
$25.1M 1.24%
608,614
– –
ITOS
25
DELISTED
iTeos Therapeutics
ITOS
$24.6M 1.22%
1,804,058
– –
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Boxer Capital held 65 positions worth $2.02B, up 0.92% from $2.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital withdrew a net $139M in Q1 2024, closing 6 positions and reducing 4 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Amylyx Pharmaceuticals worth $4.26M.

  • Boxer Capital's largest Q1 2024 buy was Amylyx Pharmaceuticals: 1,500,000 shares worth $4.26M.
  • Boxer Capital added most to Fate Therapeutics in Q1 2024, an estimated $47.8M increase.
  • Boxer Capital's biggest Q1 2024 reduction was argenx, cutting an estimated $23.2M.
  • Boxer Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $188M.
  • Boxer Capital's ten largest holdings make up 54% of its $2.02B portfolio in Q1 2024.
  • Boxer Capital opened 13 new positions and closed 6 in Q1 2024.
  • Boxer Capital's portfolio value rose 0.92% quarter-over-quarter to $2.02B.

Based on Boxer Capital's 13F filing for Q1 2024, filed 15 May 2024.